1801747-42-1 Usage
Uses
Used in Oncology:
SHP099 is used as an anti-cancer agent for its ability to inhibit the growth of various cancer types by targeting the Shp2 protein tyrosine phosphatase. Its application is particularly relevant for cancers driven by Shp2 mutations, where it can effectively suppress tumor growth and potentially enhance the efficacy of existing cancer treatments.
Used in Cancer Cell Proliferation and Survival Inhibition:
SHP099 is used as a therapeutic intervention to inhibit cellular signaling pathways such as Ras-Erk and PI3K-Akt, which are essential for the proliferation and survival of cancer cells. By blocking these pathways, SHP099 can limit the ability of cancer cells to grow and spread, offering a targeted approach to cancer treatment.
Used in Preclinical Cancer Research:
In preclinical studies, SHP099 has shown promising anti-tumor activity, making it a valuable tool for further research into the treatment of Shp2-dependent cancers. Its use in these studies helps to explore the compound's potential and optimize its application in future cancer therapies.
Used in Drug Development for Shp2-Dependent Cancers:
SHP099 is utilized in the development of new drugs targeting Shp2-dependent cancers, providing a foundation for the creation of novel therapeutics that can specifically address the needs of patients with these types of cancer. Its role in drug development is crucial for advancing cancer treatment options and improving patient outcomes.
Check Digit Verification of cas no
The CAS Registry Mumber 1801747-42-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,0,1,7,4 and 7 respectively; the second part has 2 digits, 4 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1801747-42:
(9*1)+(8*8)+(7*0)+(6*1)+(5*7)+(4*4)+(3*7)+(2*4)+(1*2)=161
161 % 10 = 1
So 1801747-42-1 is a valid CAS Registry Number.
1801747-42-1Relevant articles and documents
Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor
Garcia Fortanet, Jorge,Chen, Christine Hiu-Tung,Chen, Ying-Nan P.,Chen, Zhouliang,Deng, Zhan,Firestone, Brant,Fekkes, Peter,Fodor, Michelle,Fortin, Pascal D.,Fridrich, Cary,Grunenfelder, Denise,Ho, Samuel,Kang, Zhao B.,Karki, Rajesh,Kato, Mitsunori,Keen, Nick,Labonte, Laura R.,Larrow, Jay,Lenoir, Francois,Liu, Gang,Liu, Shumei,Lombardo, Franco,Majumdar, Dyuti,Meyer, Matthew J.,Palermo, Mark,Perez, Lawrence,Pu, Minying,Ramsey, Timothy,Sellers, William R.,Shultz, Michael D.,Stams, Travis,Towler, Christopher,Wang, Ping,Williams, Sarah L.,Zhang, Ji-Hu,Lamarche, Matthew J.
, p. 7773 - 7782 (2016/10/06)
SHP2 is a nonreceptor protein tyrosine phosphatase (PTP) encoded by the PTPN11 gene involved in cell growth and differentiation via the MAPK signaling pathway. SHP2 also purportedly plays an important role in the programmed cell death pathway (PD-1/PD-L1). Because it is an oncoprotein associated with multiple cancer-related diseases, as well as a potential immunomodulator, controlling SHP2 activity is of significant therapeutic interest. Recently in our laboratories, a small molecule inhibitor of SHP2 was identified as an allosteric modulator that stabilizes the autoinhibited conformation of SHP2. A high throughput screen was performed to identify progressable chemical matter, and X-ray crystallography revealed the location of binding in a previously undisclosed allosteric binding pocket. Structure-based drug design was employed to optimize for SHP2 inhibition, and several new protein-ligand interactions were characterized. These studies culminated in the discovery of 6-(4-amino-4-methylpiperidin-1-yl)-3-(2,3-dichlorophenyl)pyrazin-2-amine (SHP099, 1), a potent, selective, orally bioavailable, and efficacious SHP2 inhibitor.
